Desvenlafaxine
As of the edition of 20 October 2026, Desvenlafaxine is a small molecule: marketed, first approved in 2008 (US); acts on SLC6A4; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Pristiq
- First approved
- 29 February 2008 (US)
- Approvals on record
- 14 in 3 regions
- Holder of the most recent approval
- Pfizer; 6 holders in all
- Registered trials
- 75, 8 stopped early
- Disease areas
- Mental health; Nervous system; Bones, joints and muscles; Hormones; Cancer; Heart and blood vessels
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | P31645 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 5 | 3 | 2 |
| Phase 1 | 11 | 9 | 0 | 1 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 35 | 30 | 0 | 3 |
| Phase 4 | 14 | 9 | 1 | 1 |
| All trials | 75 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator, Applicant and Lead sponsor of trials | 2003 to now |
| Alembic Pharmaceuticals | Later holder | 2013 to now |
| Osmotica Pharmaceutical | Later holder | 2013 to now |
| Teva | Later holder | 2013 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2022 to now |